11th ESO-ESMO MASTERCLASS IN
CLINICAL ONCOLOGY
17-22 March 2012
Ermatingen (Lake Constance), Switzerland

Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: W. Gatzemeier, IT - R. Popescu, CH

The 2012 Masterclass is:
Part of the the Master-Online Study Program in Advanced Oncology of the University of Ulm

Held in collaboration with the Flims Alumni Club
Aims and objectives

This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, genito-urinary, gynaecological, head and neck and lung cancers.

Spotlight sessions will facilitate compact update on haematological diseases, therapeutic management of gliomas, cancer and pregnancy, side effects of systemic treatment, oral therapy, palliative care, cancer of unknown primary, sarcoma and treatment of melanoma.

Teaching format

The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The Clinical Sessions will be complemented by Tumour Board discussions. Furthermore, participants will deliver case presentations within small groups and discuss these with the chairmen and the faculty.

All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the side effects, oral therapy and palliative care sessions will be attended jointly.

The Masterclass is:

- A 5-day residential educational event
- Full immersion
- Clinically-oriented
- Multidisciplinary
- An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

Accreditation

Application for CME recognition will be submitted to the Accreditation Council for Oncology in Europe (ACOE) and to the European Society for Medical Oncology for the ESMO-MORA category 1 credits.
FACULTY (as of August 2011)

J. Bernier, Genolier Swiss Medical Network, Department of Radiotherapy, Genolier, CH
P. Casali, National Cancer Institute, Department of Medical Oncology, Milano, IT
G. Cavaletti, Bicocca University, Department of Neuroscience and Biomedical Technologies, Milan, IT
G. Curigiano, European Institute of Oncology, Division of Medical Oncology, Milano IT
A. Dietz, University of Leipzig, Department of Otolaryngology, Leipzig, DE
T. Eisen, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
C. Faivre-Finn, Christie Hospital NHS Foundation Trust, Department of Clinical Oncology, Manchester, UK
K. Fizazi, Institut Gustave Roussy, Department of Medicine, Villejuif, FR
W. Gatzemeier, Humanitas Clinical Institute, Breast Unit, Rozzano, IT
M. Ghelfmini, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
N. Harbeck, Uniklinik Köln, Breast Center, Cologne, DE
A. Horwich, The Royal Marsden Hospital, Department of Radiotherapy, Sutton, UK
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Department
P. Patel, The University of Nottingham, Division of Clinical Oncology, Nottingham, UK
N. Pavlidis, University of Ioannina, Division of Medical Oncology, Ioannina, GR
R. Popescu, Hirslanden Clinic, Tumor Center, Department of Medical Oncology, Aarau, CH
K. Redmond, Redmond Consulting, Cancer World Magazine, Lugano, CH
D. Schrijvers, Ziekenhuisnetwerk Antwerpen-Middelheim, Department of Haemato-Oncology, Antwerp, BE
D. Sebag-Montefiore, University of Leeds, Leeds Cancer Centre, Department of Clinical Oncology, Leeds, UK
C. Sessa, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
R.A. Stahel, University Hospital Zurich, Clinic and Policlinic for Oncology, Zurich, CH
E. Van Cutsem, University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Department of Oncology, Edegem, BE
G. Viale, European Institute of Oncology, Department of Pathology, and Milan University, Milan, IT
W. Weder, University Hospital Zurich, Division of Thoracic Surgery, Zurich, CH
M. Weller, University Hospital Zurich, Department of Neurology, Zurich, CH
PROGRAMME

SATURDAY, 17 MARCH

Participants' arrival, airport transfer, registration

14:30  Clinical session  Genito-urinary cancers I  Chair: K. Fizazi, FR
Prostate cancer:
  ● Local therapy: Surgery and radiotherapy  A. Horwich, UK
  ● First line endocrine treatment  A. Horwich, UK
  ● Endocrine resistant - refractory  K. Fizazi, FR

16:30  Clinical session  Genito-urinary cancers II  Chair: K. Fizazi, FR
Bladder cancer:
  ● Neoadjuvant and adjuvant chemotherapy (locally advanced disease)  TBC
  ● Metastatic disease: Systemic treatment  TBC
Renal cancer:
  ● Metastatic renal cancer: Evidence-based treatment  T. Eisen, UK

17:50  Coffee break


20:30  Dinner

SUNDAY, 18 MARCH

8:30  Clinical session  Breast cancer I  Chair: G. Viale, IT
  ● Pathology of breast cancer  G. Viale, IT
  ● Early systemic treatment I: Neoadjuvant  O. Pagani, CH
  ● Early systemic treatment I: Neoadjuvant, surgical viewpoint  W. Gatzemeier, IT
  ● Radiotherapy: Key points  J. Bernier, CH

10:30  Coffee break

11:00  Clinical session  Breast cancer II  Chair: G. Viale, IT
  ● Early systemic treatment II: Adjuvant  G. Curigliano, IT
  ● Treatment of metastatic breast cancer  N. Harbeck, DE

12:15  Tumour board  Breast cancer  G. Viale, IT - J. Bernier, CH - G. Curigliano, IT - W. Gatzemeier, IT

13:15  Lunch
14:30  Spotlight session 1  Haematological diseases  M. Ghielmini, CH
15:30  To be announced
16:00  To be announced
16:30  Spotlight session 2  Therapeutic management of gliomas  M. Weller, CH
17:00  Coffee break
17:30  Case presentations by participants
19:30  Dinner

**MONDAY, 19 MARCH**

8:30  Clinical session  Gynaecological cancers  Chair: J.B. Vermorken, BE
     • Ovarian cancer  J.B. Vermorken, BE
     • Cervical and endometrial cancers  C. Sessa, CH
10:30  Coffee break
11:00  Clinical session  Head and neck cancer  Chair: J. Bernier, CH
     • Prognostic factors and surgical approach  A. Dietz, DE
     • Radiotherapy  J. Bernier, CH
     • Systemic therapy  J.B. Vermorken, BE
13:00  Lunch
14:30  Tumour board  Gynaecological cancers  J.B. Vermorken, BE - C. Sessa, CH
15:00  Tumour board  Head and neck cancer  J. Bernier, CH - A. Dietz, DE - J.B. Vermorken, BE
15:30  To be announced
16:00  To be announced
16:30  Spotlight session 3  Cancer and pregnancy  N. Pavlidis, GR
17:00  Coffee break
17:30 Case presentations by participants
19:30 Dinner

TUESDAY, 20 MARCH

8:30 Clinical session Gastro-intestinal tumours I  Chair: E. Van Cutsem, BE
   Colon cancer:
   ● Adjuvant and neoadjuvant treatment of colorectal cancer  TBC
   ● Systemic treatment in advanced disease  E. Van Cutsem, BE
10:00 To be announced
10:30 Coffee break
11:00 Clinical session Gastro-intestinal tumours II  Chair: E. Van Cutsem, BE
   ● Management of rectal cancer (surgery and radiotherapy)  D. Sebag-Montefiore, UK
   ● Systemic treatment in early and advanced gastric cancer  TBC
12:30 Tumour board Gastro-intestinal tumours
   E. Van Cutsem, BE - D. Sebag-Montefiore, UK
13:30 Lunch
14:30 Free afternoon

WEDNESDAY, 21 MARCH

8:30 Clinical session Lung cancer and mesothelioma I  Chair: R.A. Stahel, CH
   ● Surgery  W. Weder, CH
   ● Radiotherapy  C. Faivre-Finn, UK
   ● Non-small cell lung cancer systemic therapy  R.A. Stahel, CH
10:30 Coffee break
11:00 Clinical session Lung cancer and mesothelioma II  Chair: R.A. Stahel, CH
   ● Small cell lung cancer  C. Faivre-Finn, UK
   ● Mesothelioma  R.A. Stahel, CH
12:00 Tumour board Lung cancer
   R.A. Stahel, CH - W. Weder, CH - C. Faivre-Finn, UK
13:00 Lunch
14:15 Joint medics and nursing session
Side effects of systemic treatment and their management
- Cardiovascular toxicity
- Skin toxicity
- Neurotoxicity

15:30 Joint medics and nursing session
Oral therapy: Adherence, compliance and drug interaction

16:00 Coffee break

16:30 Joint medics and nursing session
Palliative care
- Pain control
- Advanced disease management

18:00 Case presentations by participants

19:30 Dinner

THURSDAY, 22 MARCH

8:30 Spotlight session 4 Cancer on unknown primary
N. Pavlidis, GR

9:30 Spotlight session 5 Sarcoma
P. Casali, IT

10:30 Coffee break

11:00 Spotlight session 6 Advances in systemic treatment of melanoma
P. Patel, UK
ORGANISING SECRETARIAT
Francesca Marangoni
European School of Oncology
Via del Bosso, 4
20123 Milan, Italy

Email: fmarangoni@eso.net
Phone: +39 02 85464525
Fax: +39 02 85464545
www.eso.net

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
SUCCESSFUL APPLICANTS ARE GRANTED FREE REGISTRATION AND ACCOMMODATION

APPLICATION DEADLINE: 1 DECEMBER 2011

Information and online application available at: www.eso.net

IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

● Age between 30 and 40 years
● At least 2-3 years’ experience in medical oncology or clinical oncology
● Involvement in scientific activities
● Fluency in English

HOW TO APPLY

Interested oncologists should apply online at www.eso.net providing:

● Letter describing motivation for attending
● Supporting letter from head of department or mentor
● CV with list of publications (if the list of publications is not provided, it will be assumed that no articles have been published)
● Abstract, please see below, relating to one of the subjects of the Masterclass: genito-urinary cancers, breast cancer, gynaecological cancers, head and neck cancer, gastro-intestinal cancers, lung cancer

The abstract of one page should describe a clinical case, not a clinical study, in the form of a clinical grand round with:

● Diagnostic considerations
● Treatment
● Results, follow-up
● At least three questions proposed for discussion with the faculty

ACKNOWLEDGEMENTS

ESO wishes to express its appreciation to Union Bank of Switzerland (UBS) and Wolfsberg Centre for their consideration and support to the 2012 Masterclass.

The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are:

● Platinum members: Amgen and Eisai
● Gold members: Eli Lilly, GlaxoSmithKline Oncology and Merck Serono
● Silver members: Genomic Health, Novartis Oncology and Sanofi-Aventis